Visual Abstract

The Onduo Virtual Diabetes Clinic (VDC) for people with T2D combines a mobile app, remote personalized lifestyle coaching, connected devices and video consultations with endocrinologists for medication management and prescription of real-time CGM for intermittent use. A recent prospective single-arm trial reported a reduction in A1c of 1.6%±1.0 (p<0.001), from 8.9%±1.0 to 7.3%±0.9, and a significant improvement in CGM-derived glycemic metrics at 4-mo in adults with suboptimally controlled T2D (n=55) who participated in the VDC. The present analysis examined A1c at 1-yr after an additional 7-mo follow-up period of self-management without active VDC intervention. Of the 4-mo active phase study cohort, 94.5% (n=52) provided a A1c measurement at 1-yr. Participants were age 57.9±11.3 yr, 40.4% female with baseline A1c 8.9%±0.9. Change in A1c is presented in the Table for baseline, 4-mo and 1-yr time points. The significant reduction in A1c observed after the 4-mo active intervention was maintained at 1-yr. No significant changes were observed between 4-mo and 1-yr.

In conclusion, these data suggest that short-term participation in the VDC program by adults with suboptimally controlled T2D resulted in an improvement in A1c at 1-yr lasting beyond the active phase of VDC participation. This durable improvement may be associated with optimized medication regimens and behavior change.


A. R. Majithia: Consultant; Self; Onduo LLC., Speaker's Bureau; Self; Pfizer Inc. H. Zisser: Employee; Self; Verily Life Sciences, Stock/Shareholder; Self; Verily Life Sciences. C. Kusiak: Employee; Self; Verily Life Sciences. A. Armento lee: Employee; Self; Verily Life Sciences. F. R. Colangelo: None. R. Romanelli: None. S. Robertson: None. D. M. Erani: None. J. E. Layne: Employee; Self; Onduo LLC. R. F. Dixon: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at